

INFLAMMATORY BOWEL DISEASE SPECIALTY CARE PROGRAM

Phone: **844-422-6400**

• Fax: **888-850-4018**

1 PATIENT INFORMATION:

Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Alt. Phone: _____

Email: _____

DOB: _____ Gender: ☐ M ☐ F Caregiver: _____

Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____

NPI: _____ DEA: _____

Tax I.D.: _____

Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____

☐ Crohn's Disease ☐ Ulcerative Colitis ☐ Irritable Bowel Syndrome

ICD-10: _____

Other: _____

Serious or active infection present? ☐ Yes ☐ No

Hep B ruled out or treatment started? ☐ Yes ☐ No

TB Test: ☐ Positive ☐ Negative Date: _____

If Prior Authorization is Denied:

☐ Automatically Draft Appeal for Review

☐ Send Formulary Preferred Alternatives

Prior
Failed Treatments:

Indicate Drug Name
and Length of Treatment:

☐ 5-ASA _____

☐ Biologics _____

☐ Corticosteroids _____

☐ Immunosuppressants _____

☐ Methotrexate _____

☐ Surgery _____

☐ Other _____

4 PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

| Medication | Dosage & Strength | Direction | QTY | Refills |
|-----------------------------------|---|--|--------|---------|
| <input type="checkbox"/> CIMZIA® | <input type="checkbox"/> Prefilled Syringe Starter Kit <input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Powder | <input type="checkbox"/> Induction Dose: Inject 400mg SC on day 1, 14 and 28 <input type="checkbox"/> Maintenance: Inject 400mg SC every 4 weeks | 6 2 | 0 |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Disease/ Ulcerative Colitis Starter Kit <input type="checkbox"/> 40mg/0.8ml Pen <input type="checkbox"/> 40mg/0.8ml Prefilled Syringe <input type="checkbox"/> Patient has signed HUMIRA Complete form | <input type="checkbox"/> Induction Dose: Inject 160mg SC on day 1, then 80mg SC on day 15, then switch to maintenance dose <input type="checkbox"/> Maintenance: Inject 40mg SC every other week | 6 2 | 0 |
| <input type="checkbox"/> SIMPONI® | <input type="checkbox"/> 100mg/ml Smartject® Autoinjector <input type="checkbox"/> 100mg/ml Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject 200mg SC at week 0, 100mg SC at week 2 and then switch to maintenance dose <input type="checkbox"/> Maintenance: Inject 100mg SC every 4 weeks | 3 1 | 0 |
| <input type="checkbox"/> UCERIS® | <input type="checkbox"/> 9mg Tablets | <input type="checkbox"/> Take one tablet daily in the morning with or without food | 30 | 1 |
| <input type="checkbox"/> XIFAXAN® | <input type="checkbox"/> 550mg Tablets | <input type="checkbox"/> Take one tablet three times daily for 14 days | 42 | |
| <input type="checkbox"/> _____ | _____ | _____ | | |

5 INJECTION TRAINING: ☐ To Be Administered by Pharmacist ☐ Pharmacist to Provide Training ☐ Patient Trained in MD Office ☐ Manufacturer Nurse Support

6 PICK UP OR DELIVERY: ☐ Delivery to Patient's Home ☐ Delivery to Physician's Office ☐ Pharmacy to Coordinate

7 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

8 PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____

Substitution Permitted

Signature: _____ Date: _____

Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of pay.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.